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Context: T helper (Th) cells as an important part of  the immune is responsible for elimination 
of  invading pathogens. But, if  Th cell responses are not regulated effectively, the autoimmune 
diseases might develop. The Th17 subset usually produces interleukin-17A which in 
experimental models of  organ-specific autoimmune inflammation is very important.
Evidence Acquisitions: Directory of  open access journals (DOAJ), Google Scholar, Embase, 
Scopus, PubMed and Web of  Science have been searched.
Results: Fifty-six articles were found and searched. In the present review article, we tried 
to summarize the recently published data about characteristics and role of  Th1 and Th17 
cells and discuss in detail, the potential role of  these T helpers immune responses in renal 
inflammation and renal injury, focusing on glomerulonephritis. Published papers in animal 
and human studies indicated that autoimmune diseases such as rheumatoid arthritis and 
multiple sclerosis, classically believed to be Th1-mediated, are mainly derived from a Th17 
immune response. Identification of  the Th17 subgroup has explained seemingly paradoxical 
observations and improved our understanding of  immune-mediated inflammatory responses. 
Conclusions: Secretion of  IL-17A, as well as IL-17F, IL-21, IL-22, suggests that Th17 subset 
may play a crucial role as a pleiotropic pro-inflammatory Th subset. There is experimental 
evidence to support the notion that Th1 and Th17 cells contribute to kidney injury in renal 
inflammatory diseases like glomerulonephritis.
ABSTRACT
1. Context
Renal failure is considered as the most serious outcome 
of  the chronic kidney disease (CKD) in which the 
symptoms are mainly caused by complications of 
decreased kidney function. In this situation when 
the symptoms are severe and the renal function 
permanently failed, they might be treated only by 
transplantation or dialysis. The kidney failure in this 
situation is known as end-stage renal disease (1-5). 
2. Evidence acquisition
We searched various electronic databases, including 
Directory of  open access journals (DOAJ), Google 
Scholar, Embase, Scopus, PubMed and Web of 
Science. We searched keywords of  renal injury, 
glomerulonephritis, CKD and autoimmune disease. 
For this review, fifty-six articles were found and 
searched.
3. Results
The kidneys are frequently targeted by local 
manifestations of  systemic  autoimmunity  or 
pathogenic immune responses such as renal 
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recently uncovered several underlying mechanisms 
that might be used to explain the previously enigmatic 
immunopathology of  many renal diseases. These 
mechanisms include kidney-specific damage-
associated molecular patterns that cause crosstalk 
between renal dendritic cells and T cells, development 
of  kidney-targeting autoantibodies, sterile 
inflammation, and molecular mimicry with microbial 
pathogens. Infectious and cardiovascular diseases are 
the most important reasons for the high mortality 
and morbidity associated with CKD and end-stage 
renal disease (ESRD). It is estimated that more than 
15% of  the adult subjects have some degree of  CKD, 
and that dialysis which is applied on about 0.1% of 
the population consumes about 2% of  total health 
expenditure in most developed countries (6). The T 
cells are involved in a lot of  immune-mediated diseases, 
including the ones affecting kidney (7,8). They act as 
“helpers” for B cells which produce autoantibodies 
against kidneys, for example in Goodpasture 
syndrome, a form of  type 2 hypersensitivity, or 
antibodies which form immune complexes, that upon 
glomerular deposition induce type 3 hypersensitivities, 
also known as immune complex glomerulonephritis 
(GN). However, there is a report suggesting a role for 
the fourth “cellular” delayed type of  hypersensitivity 
in human glomerulonephritis (9).
3.1. Differentiation and function of  Th1 and Th17 cells
CD4+ T-helper cells have been shown to play a 
crucial role in the regulation of  the adaptive immune 
response. Activation of  CD4+ T-helper cells is critical 
for the control and elimination of  invading pathogens, 
however, autoimmune disease might arise if  CD4+ T 
cells become activated in response to self-antigens. 
A key mechanism used by the immune system to 
prevent autoimmunity is to precisely regulate the 
differentiation and activation of  CD4+ T-helper cells 
(10). Based on the cytokine secretion and expression 
of  specific transcription factors, the CD4+ T cells 
are classified into four major sub-groups: Th1, Th2, 
Th17, and regulatory T cells (Tregs), although further 
T-helper cell lineages might exist (11). It has been 
suggested that CD4+ T cells might be subgroup 
into two independent subsets, called Th1 and Th2 
cells (12). Th1 cells mainly produce interferon-γ 
(IFN-γ), which is crucial for macrophage activation, 
and are predominantly involved in the clearance of 
intracellular pathogens. Th2 cells are, in contrast, 
characterized by the production of  IL-4, IL-5, and 
IL-13 and are critical for eosinophil recruitment, 
IgE production, and participate in the elimination of 
extracellular pathogens. Interleukin-12, is critical for 
Th1 differentiation, however, IL-4 has the major role 
in Th2 differentiation. Data from experimental and 
human experimental models have provided strong 
evidence that, Th1 cells might also be involved in cell-
mediated autoimmune disease (for example, multiple 
sclerosis, Crohn’s disease, rheumatoid arthritis, and 
crescentic glomerulonephritis), whereas Th2 cells 
are associated with allergic diseases. Th17 cells differ 
from Th1 and Th2 cells by cytokines that drive their 
differentiation and also by their cytokine expression 
profile. Under the influence of  IL-6, transforming 
growth factor-β (TGF-β), IL-1, and IL-21, the key 
transcription factors are known to induced and mediate 
Th17 cell differentiation in humans and animals (11). 
Remarkably, recent studies have indicated that there 
might be also TGF-β-independent pathways for 
differentiation of  Th17 cells (13). Interleukin-23 is also 
essential for expansion and stabilization of  the Th17 
cell population. Th17 cells are implicated in organ-
specific autoimmune inflammation and their roles in 
glomerulonephritis. The discovery of  Th17 cells in 
mice came from the experiments that documented 
the effects of  IL-12 and IL-23 in experimental murine 
models of  rheumatoid arthritis, inflammatory bowel 
disease and multiple sclerosis (14,15). In all three 
models of  autoimmune disease, IL-23 have played 
an important role whereby IL-23-deficient have been 
completely protected from disease. Interleukin-12 
and IL-23 are heterodimeric cytokines of  the same 
family and share the same p40 subunit with different 
second subunits, p35 and p19, respectively (16). 
It was previously believed that IL-12 was the key 
cytokine in inflammatory diseases as neutralizing 
antibodies to p40 ameliorated disease in experimental 
autoimmune encephalomyelitis (EAE) (17). 
Interleukin-12 had been known to direct Th1– IFN-γ 
responses (18,19), and inflammatory diseases were 
known to cause by an unregulated Th1 response. 
However, it was unexpectedly observed that mice 
deficient in IFN-γ or its receptor were not protected 
from EAE (20,21). Shortly after report of  these 
paradoxical observations, the IL-23 p19 subunit was 
discovered (16) and as named, IL-23 which is now 
regarded as the key cytokine in the pathogenesis of 
mouse inflammatory bowel disease and collagen 
induced arthritis (CIA). Experimental trials in EAE 
have shown that IL-23 is responsible for driving the 
development and expansion of  the distinct Th17 
subset that produces tumor necrosis factor (TNF)-α, 
IL-6, IL-17A and IL-17F (22). Furthermore, the 
pathogenicity of  IL-23-driven Th17 cells has been 
proven by transfer of  these cells into recipient animals 
that consequently developed severe clinical signs of 
Azadegan-Dehkordi F et al.
Journal of  Nephropathology, Vol 4, No 2, April 2015        www.nephropathol.com34
EAE (22). Neutralization of  IL-17A has been shown 
to correlate with protection from EAE (22). IL-17-
deficient mouse is resistant to both EAE and collagen 
induced arthritis (23,24). 
Th17 cells cause inflammation by tumor necrosis 
factor a (TNF-α), IL-17A, IL-17F, IL-21 and IL-
22, leading to up-regulated expression of  numerous 
pro-inflammatory cytokines and chemokines such 
as CXCL1, CXCL8, and CCL2 and IL-6, by local 
tissue and infiltrating inflammatory cells. These 
inflammatory mediators may further increase the 
recruitment of  different leukocyte subsets, ultimately 
leading to target organ injury. Interleukin-17 
was isolated and characterized 10 years before 
identification of  the Th17 lineage from a rodent CD4+ 
T-cell cDNA library (25). It represents the founder 
member of  a cytokine family which includes IL-17, 
IL-17B, IL-17C, IL-17D, IL-17E, IL-17F and the 
receptors IL-17RA, IL-17RB, IL-17RC, IL-17RD, and 
IL-17RE (26). The biologically most potent member 
of  the family is IL-17A that binds to the IL-17RA and 
IL-17RC receptors. 
The main function of  the Th17 immune response 
is in the defense against fungal and bacterial 
pathogens (27). The presence of  IL-17-producing T 
cells in biopsies of  patients with multiple sclerosis, 
rheumatoid arthritis and Crohn’s disease, suggests that 
the Th17 immune response may also contributes to 
tissue injury in human autoimmune and inflammatory 
diseases (28). However, at the site of  inflammation, 
the numbers of  IL-17-producing T cells are often 
low and they usually are found together with a more 
prominent infiltrate of  Th1 cells. This may suggest 
that the combined action of  pathogenic Th1 and 
Th17 cells might be responsible for establishment of 
autoimmunity in humans.
3.2. Correlation between Th17 cells and Treg and Th1 cells
The polarization of  naive CD4+ Th cells into Th17 
and Treg cells requires TGF-β. Unopposed TGF-β 
stimulation in the context of  antigen presentation 
induces Foxp3 expression and immunoregulation 
Treg commitment. However, in the context of 
inflammation signaled by presence of  IL-6, TGF-β 
drives inflammation and Th17 differentiation (29). 
Furthermore, IL-6 inhibits the differentiation of 
Tregs and generation of  Foxp3. It facilitates Th17 
effector cells by reducing the functional capacity of 
Tregs, too (30). These observations may suggest a 
relationship between Th17 and Tregs differentiation 
depending on the presence of  inflammatory danger 
signal IL-6 (31). Interleukin-21, the Th17-amplifying 
cytokine, inhibits TGF-β induction of  Tregs (32,33). 
Interleukin-27, an IL-2 family cytokine, is a negative 
regulator of  Th17 development (34). Interleukin-2 also 
induces Tr1 cells, a Treg population characterized by 
IL-10 expression (35). Interleukin-10 is also a negative 
regulator of  Th17 development (36). Interleukin-17A 
receptor is expressed on differentiated Th1 cells. In 
vitro experiments show that IL-17A is able to down-
regulate expression of  the Th1 transcription factor, 
T-bet (37). These may suggest that Th17 cells are 
able to regulate pathogenic Th1- mediated tissue 
inflammation (38). In the presence of  IL-12 or IL-
23 and absence of  TGF-β, differentiated Th17 
cells lose IL-17A and IL-17F secretion and become 
IFN-γ-producing cells (39). However, this switch is 
dependent on the Th1 transcriptions factors, STAT4 
and T-bet, and show that Th17 cells might be not 
terminally differentiated but are capable of  substantial 
plasticity.
3.3. Direct evidence implicating Th1 and Th17 cells in the 
pathogenesis of  proliferative glomerulonephritis
Direct evidence that Th1 and Th17 cells may induce 
proliferative glomerulonephritis has been reported, 
where ovalbumin is planted in glomeruli of  Rag1-/- 
mice which are deficient in T and B cells. Injection of 
either ovalbumin-specific Th1 or Th17 polarized cells 
will induce proliferative glomerulonephritis (40-42). 
Th17 cell induced injury has been shown to develop 
early however, Th1 cell-mediated glomerulonephritis 
is more delayed and featured enhanced macrophage 
activation. These findings may support a model in 
which some forms of  proliferative glomerulonephritis 
may be Th17 cell predominant, while others are Th1 
mediated. It may also suggest that Th17 cells might 
dominate glomerular diseases that are neutrophil 
rich. However, other recent evidence in autoimmune 
renal disease suggests a role for Th17 in macrophage 
recruitment (43).
3.4. Th17 cells in anti-GBM glomerulonephritis
Anti-GBM glomerulonephritis has been suggested 
to be Th1 mediated due to the predominance of 
the Th1-associated IgG antibody subclasses (IgG1 
and/or IgG3) and the presence of  delayed-type 
hypersensitivity (DTH) effectors deposited in the 
kidney (41). It should be noted that the presence 
of  DTH effectors may not be solely reliant on a 
Th1-mediated response as human trans-vivo DTH 
experiments that cell mediated autoimmunity against 
collagen (V) is dependent on IL-17, but not on IFN-γ 
(44). Moreover, the DTH response is diminished 
upon depletion of  ether one of  the human Th17-
inducing cytokines (TGF-β or IL-1β), or CD4+ cells 
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suggesting that Th17-mediated responses alone are 
able to mediate the DTH-like glomerular effects seen 
in patients with crescentic GN (44). Experimental 
autoimmune anti-GBM studies have shown that 
animals deficient in IFN-γ are not protected from 
disease and may develop more severe signs of  clinical 
disease (45,46). 
 It has also been shown that when IL-23p19-deficient 
(IL-12 intact, IL-23 deficient) and IL-12p40 (IL-
12 and IL-23 deficient) mice are protected from 
the induction of  experimental autoimmune anti-
GBM but IL-12p35-deficient (IL-12 deficient, IL-
23 intact) mice are not (46). In this experimental 
model, the autoimmunity was induced in mice by 
repeated immunization with mouse alpha 3 chain 
Type IV collagen non-collagenous domain (a3(IV)
NC1), which is the known target autoantigen in 
human autoimmune anti-GBM GN disease and 
Goodpasture’s disease (41). These observations may 
suggest that IL-23 and hence the Th17 cell subset 
are necessary for the induction of  autoimmune renal 
disease. This is consistent with other suggestions in 
autoimmune inflammatory models of  rheumatoid 
arthritis (47) and multiple sclerosis (20) that have 
proven the IL-23-driven Th17 cell subset essential 
in autoimmune pathogenesis. Experimental models 
have also been used to study the role of  Th17 cells 
in GN. In a study where, sheep antimouse GBM 
antibodies were used to induce GN, it showed that 
IL-17A- and IL-23p19-deficient mice were protected 
from glomerular injury (48). IL-17A upregulated the 
expression of  pro-inflammatory chemokines: CCL2, 
CCL3 and CCL20 in mice mesangial cells in vitro 
(48). In separate experiments using this model, it has 
also been shown that Th17 cells use the chemokine 
receptor CCR6 (which binds to CCL20) to migrate 
into the kidney (49).
3.5. Pauci-immune ANCA-associated glomerulonephritis
Despite the paucity of  immunoglobulin deposition 
in the glomeruli, this form of  crescentic 
glomerulonephritis is correlated with circulating anti-
neutrophil cytoplasmic antibodies (ANCA), which 
are largely specific for two neutrophil constituents, 
proteinase-3 or myeloperoxidase (MPO). There 
is evidence suggesting a crucial role for ANCA in 
pauci-immune crescentic glomerulonephritis. Cellular 
and humoral MPO-specific immune responses 
have been demonstrated to promote crescentic 
glomerulonephritis. Furthermore, MPO has been 
shown in these glomerular lesions as a planted antigen 
(50-52). Percentages of  IL-17A-producing activated 
T cells is increased in ANCA-positive Wegener’s 
granulomatosis patients (53). Peripheral blood 
mononuclear cells (PBMCs) from patients with active 
Churg–Strauss syndrome demonstrated a higher IL-
17A production than normal controls (54). Higher 
levels of  serum IL-17A, IL-23, MPO and Pr3-specific 
Th17 cells are present in subjects with ANCA-
associated vasculitis (55). MPO-ANCA triggers the 
production of  IL-6, IL-17A and IL-23 and increases 
the activation of  neutrophils, conditions that promote 
Th17-mediated autoimmunity (56). The role of  IL-
17A has been examined using IL-17A-deficient mice 
in anti-MPO glomerulonephritis. The mice lacking 
IL-17A were protected from disease, and IL-17A 
promoted neutrophil recruitment to glomeruli (43). 
In addition to its effects on neutrophils, IL-17A has 
been shown to promote macrophage recruitment in a 
neutrophil-dependent manner.
4. Conclusions
Identification of  the Th17 subgroup has explained 
seemingly paradoxical observations and improved our 
understanding of  immune-mediated inflammatory 
responses. Secretion of  IL-17A, as well as IL-17F, IL-
21, IL-22, suggests that Th17 subset may play a crucial 
role as a pleiotropic pro-inflammatory Th subset. 
There is experimental evidence to support the notion 
that Th1 and Th17 cells contribute to kidney injury in 
renal inflammatory diseases like glomerulonephritis. 
Studies have suggested that Th17 cells are not 
differentiated cells and are capable of  switching to 
a Th1 phenotype (39). It has been hypothesized that 
following its differentiation and expansion by IL-6, 
TGF-β, IL-21 and IL-23, the Th17 can be recruited to 
the kidney and mediate tissue damage by mobilizing 
and activating neutrophils, planting neutrophil 
chemoattractants in the target organ, which in turn 
cause injury to the target tissue. 
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